Objective To compare the efficacy of serological diagnosis model (APRI,FIB-4,Forns index) and Transient elastography (FibroScan) in evaluation of liver fibrosis in chronic hepatitis B (CHB) patients with mild hepatic steatosis. Methods Three hundred and nine patients with CHB proven by liver biopsy were recruited in this study. Out of them,194 had no,and 115 had hepatic steatosis. All patients with CHB were checked-up by FibroScan to get the liver stiffness measurement (LSM),and we collected the laboratory indexes to calculate the APRI,FIB-4 and Forns index. We evaluated the efficacies of the four methods in diagnosis of liver fibrosis based on liver biopsy as the gold standard. Results The differences of LSM,APRI,FIB-4,Forns index in patients with and without liver steatosis were not statistically significant (all P>0.05);The area under the ROC curve (AUROC) of LSM,APRI,FIB-4 and Forns index for the diagnosis of obvious liver fibrosis (≥F2) in CHB patients without hepatic steatosis were 0.77,0.69,0.72 and 0.69 (all P <0.05),and its corresponding cut-off-values were 10.2,0.5,0.9 and 5.3;the AUROC for the diagnosis of liver cirrhosis(≥F4) were 0.86,0.72,0.77 and 0.77 (all P<0.05),and its corresponding cut-off-value were 11.8,0.6,1.3 and 5.1;The AUROC of LSM,APRI,FIB -4 and Forns index for the diagnosis of obvious liver fibrosis (≥F2) in CHB patients with mild hepatic steatosis were 0.79,0.67,0.74 and 0.77 (all P <0.05) and its corresponding cut-off-valures were 9.7,0.4,1.1 and5.4;the AUROC for the diagnosis of liver cirrhosis (≥F4) were 0.88,0.71, 0.75 and 0.78 (all P<0.05),and its corresponding cut-off-values were 11.8,1.1,1.5 and 5.4;The APRI and FIB-4 didn’t find light hepatic fibrosis in the two groups (P>0.05;The efficacy of LSM for the diagnosis of hepatic fibrosis was superior to APRI. Conclusions The APRI assessment for the liver fibrosis in patients with CHB with mild liver steatosis is poor,while the LSM,FIB-4 and Forns index are good. The mild hepatic steatosis might affect the diagnosis of Forns index in CHB patients with liver fibrosis.%目的：比较血清学诊断模型APRI、FIB-4和Forns指数及FibroScan检查评估合并轻度肝脂肪变的CHB患者肝纤维化的价值。方法在309例经肝活检病理学检查确诊的CHB患者中，194例无肝脂肪变，115例合并轻度肝脂肪变，同期行FibroScan检查，得到肝硬度值（LSM），收集实验室检查指标，根据公式计算出相应的APRI、FIB-4、Forns指数。以肝组织病理学表现为金标准，根据受试者工作曲线（ROC）评价4种方法诊断两组患者肝纤维化的效能。结果两组患者LSM、APRI、FIB-4、Forns指数差异均无统计学意义（P均＞0.05）；在未合并肝脂肪变组，LSM、APRI、FIB-4、Forns指数诊断CHB患者明显肝纤维化（≥F2）的ROC曲线下面积（AUROC）分别为0.77、0.69、0.72、0.69（P均<0.05），其相应的截断点分别为10.2、0.5、0.9、5.3；诊断肝硬化（≥F4）时，其AUROC分别为0.86、0.72、0.77、0.77（P均<0.05），其相应的截断点分别为11.8、0.6、1.3、5.1；在合并肝脂肪变组，它们诊断CHB患者≥F2肝纤维化的AUROC分别为0.79、0.67、0.74、0.77（P均<0.05），其相应的截断点分别为9.7、0.4、1.1、5.7；诊断≥F4的AUROC分别为0.88、0.71、0.75、0.78（P均<0.05），其相应的截断点分别为11.8、1.1、1.5、5.4；APRI 和FIB-4不能诊断两组患者轻度肝纤维化（P＞0.05）；LSM诊断两组≥F2肝纤维化及≥F3或≥F4进展性肝纤维化或肝硬化的效能均优于APRI。结论 APRI评价合并轻度肝脂肪变的CHB患者肝纤维化效能较差，而LSM、FIB-4、Forns指数诊断效能较好，其中轻度肝脂肪变可能影响Forns指数诊断CHB患者肝纤维化效能。
展开▼
